|
Calistoga Pharmaceuticals |
|
|
2101, 4th Avenue, Suite 1960
Seattle, WA 98121 USA
phone:(206) 728-4700
fax:(206) 728-4777
|
|
| Symbol |
private |
| Founded |
0 |
| Employees |
|
|
|
| www.calistogapharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases |
|
| Management |
| Carol Gallagher, Pharm. D., Chief Executive Officer; W. Michael Gallatin, Ph.D., President; Neill Giese, Ph.D., Chief Scientific Officer; Clifford J. Stocks, Chief Business Officer; Roger Ulrich, Ph.D., Chief Development Officer; Albert S. Yu, M.D., Vice President, Clinical Affairs and Chief Medical Officer |
| |
|
|
| |
|
| Keywords |
| Kinase inhibitors, small molecule therapeutics, asthma, cancer, rheumatoid arthritis, non-hodgkin's lymphoma, mantle cell lymphoma, chronic lympocytic leukemia |
|
|
|
| Description |
|
Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases. Calistoga Pharmaceuticals has a portfolio of proprietary compounds selectively targeting the isoforms of the PI3 kinase pathway: CAL-101: an oral, p110δ (delta) selective PI3 kinase inhibitor under clinical evaluation in patients with hematologic malignancies; CAL-120: an oral, PI3 kinase inhibitor with p110δ and, p110β (beta) inhibition under preclinical evaluation for the treatment of patients with solid tumor malignancies; CAL-263: an oral, p110δ selective PI3 kinase inhibitor advancing toward Phase 2 for treatment of patients with inflammatory diseases. |
|
| Products / Services |
The company?s initial product indicated for cancer was recently shown in Phase I clinical trials to be effective against refractory indolent non-hodgkin?s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. The company?s medicine to treat inflammatory diseases, including asthma and rheumatoid arthritis, has also produced effective results in Phase I clinical trials and is set up to enter Phase II clinical trials in 2010.
|
|
| Technology / Differentiation |
| PI3 kinase has been found to be part of the adverse biological signaling pathways that lead to disease states, and the company is the first to develop small molecule therapeutics that target specific isoforms of PI3 kinase shown to be injurious. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members